


PRODUCT INFORMATION



Ilorasertib

Item No. 34204

CAS Registry No.: 1227939-82-3
Formal Name: N-[4-[4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl]phenyl]-N'-(3-fluorophenyl)-urea
Synonym: ABT-348
MF: C₂₅H₂₁FN₆O₂S
FW: 488.5
Purity: ≥98%
UV/Vis.: λ_{max}: 261 nm
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Ilorasertib is supplied as a solid. A stock solution may be made by dissolving the ilorasertib in the solvent of choice, which should be purged with an inert gas. Ilorasertib is soluble in ethanol.

Description

Ilorasertib is a multi-kinase inhibitor.¹ It inhibits Aurora C, VEGFR1, VEGFR2, FLT3, colony-stimulating factor 1 receptor (CSF1R), and Aurora B (IC₅₀s = 1, 1, 2, 1, 3, and 7 nM, respectively). It also inhibits PDGFRα, PDGFRβ, c-Kit, VEGFR3, and Aurora A (IC₅₀s = 11, 13, 20, 43, and 120 nM, respectively). Ilorasertib inhibits autophosphorylation of Aurora A, -B, and -C in HeLa cells with IC₅₀ values of 189, 13, and 13 nM, respectively. It inhibits proliferation of a variety of cancer cells, including MV4-11 acute myeloid leukemia (AML), SUP-B15 acute lymphocytic leukemia (ALL), and H1299 non-small cell lung cancer (NSCLC) cells (IC₅₀s = 0.3, 4, and 2 nM, respectively). It decreases histone H3 phosphorylation in blood-borne tumor cells in an engrafted mouse model of leukemia when administered at a dose of 25 mg/kg and reduces tumor growth in fibrosarcoma, pancreatic carcinoma, ALL, and multiple myeloma mouse xenograft models.

Reference

1. Glaser, K.B., Li, J., Marcotte, P.A., *et al.* Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families. *J. Pharmacol. Exp. Ther.* **343**(3), 617-627 (2012).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/18/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM